Ofloxacina

/ BioAvenir

In patients with mormal renal function:
Urinary tract infections: 1 x 100-200 mg/day.
Kidney and genital infections: 2 x 100-200 mg/day.
Respiratory infections, bone and joint infections, skin and soft tissue infections, abdominal infections, septicem: 2 x 200 mg/day.
All within a 12 hours interval.
In cases of variable sensitivity, severe/complications infections or insufficient response: The dose can be adjust to 2 x 400 mg/day.
See prescribing information for full details.

Infections of kidney, urinary tract, genital organs, respiratory tract, chronic and recurrent ear, nose and throat, skin and soft tissues, bones and joints, bacterial enteritis, abdominal cavity, including pelvis minor septicemia caused by ofloxacin sensitive microorganisms. Prevention of infections in patients with a significant reduction of resistance to infections.

Known hypersensitivity to ofloxacin or other quinolones, epilepsy, children and adolescents, pregnancy and lactation, G6PD deficiency. Patients with known or suspected CNS disorders that may predispose to lower the seizure threshold.

Dosage adjustment is necessary in patients with impaired renal function. The occurrence of severe and persistent diarrhea might be a symptom of pseudomembranous colitis. If this is diagnosed, treatment must be immediately discontinued and a specific antibiotic must be used and the administration of anti-peristaltic drugs should be avoided. Excessive sunlight should be avoided during treatment due to photosensitivity risk. Must not be prescribed as a drug of first choice for nosocomials respiratory infections, except when there is a precise bacteriological study. During treatment of infections caused by pseudomonas aeruginosa and staphylococcus aureus, the occurrence of resistant mutants is described, and another antibiotic might be needed. If neurological adverse reactions occur, observed in some cases right after the first dose, the physician must be informed.

Reports of adverse reactions in 2-12% of the patients. Nausea, abdominal pain, diarrhea and vomiting. Pseudomembranous colitis may develop. If the latter is even suspected, discontinue immediately and give appropriate treatment. Headache, insomnia, dizziness, sleep disorders, visual disturbances. Rash, pruritus.
See product information for full details.

Glibenclamide, other drugs that undergo renal tubular secretion (e.g. probenecid, cimetidine, frusemide and methotrexate). Determination of opiates or porphyrins in urine may give false-positive results. Hypertensive medications.